About
Op2lysis develops innovative medicines to safely lyse hematomas and blood clots formed during brain thrombosis, specifically targeting hemorrhagic stroke with its NANOp2Lysis® technology and optimized thrombolytic agent OptPA.
Explore Op2lysis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.